The immunosuppressant 15-deoxyspergualin [correction of 1,5- deoxyspergualin] reveals commonality between preT and preB cell differentiation

doi:10.1084/jem.183.6.2427

This Article

	Full Text (PDF, 1583K)
	Alert me when this article is cited
	Citation Map

Services

	Email this article
	Similar articles in this journal
	Similar articles in PubMed
	Alert me to new content in the JEM
	Download to citation manager

Citing Articles

	Citing Articles via HighWire
	Citing Articles via CrossRef
	Citing Articles via Google Scholar

Google Scholar

	Articles by Wang, B.
	Articles by Mathis, D.
	Search for Related Content

PubMed

	PubMed Citation
	Articles by Wang, B.
	Articles by Mathis, D.


Social Bookmarking

	What's this?

ARTICLES

The immunosuppressant 15-deoxyspergualin [correction of 1,5- deoxyspergualin] reveals commonality between preT and preB cell differentiation

B Wang, C Benoist and D Mathis
Institut de Genetique et de Biologie Moleculaire et Cellulaire (CNRS/INSERM/ULP), de Strasbourg, France.

15 [correction of 1,5] deoxyspergualin (DSG) is a potent immunosuppressant whose mechanism of action is still somewhat of a mystery. We have studied the generation of lymphocytes in mice treated with this drug. The differentiation of T cells in the thymus was blocked at an important early control point: the CD4-8- --> CD4+8+ transition, known to depend on the expression of a preTCR complex that includes the variable TCR-beta, but not TCR-alpha, chain. In clear contrast, a later control point, the CD4+8+ --> CD4+8- or CD4-8+ transition, dependent on the display of a conventional alpha:beta TCR complex, appeared unaffected, as did activation of mature T cells both in vitro and in vivo. Interestingly, preB cell differentiation in the bone marrow was blocked at a precisely equivalent point: the A-C --> C' transition, controlled by expression of a pre-receptor complex containing the Ig heavy, but not light, chain. Mature B cells seemed unperturbed. These findings have theoretical implications, suggesting common signaling pathways in early lymphocytes that are distinct from those employed by more mature cells, and are also of practical interest, to be considered in the design of DSG treatment protocols.
Add to CiteULike CiteULike Add to Complore Complore Add to Connotea Connotea Add to Del.icio.us Del.icio.us Add to Digg Digg Facebook Add to Reddit Reddit Add to Technorati Technorati Twitter What's this?

This article has been cited by other articles:

Friese, M. A., Montalban, X., Willcox, N., Bell, J. I., Martin, R., Fugger, L. (2006). The value of animal models for drug development in multiple sclerosis. Brain 129: 1940-1952 [Abstract] [Full Text]
Birck, R., Newman, M., Braun, C., Neumann, I., Nemoto, K., Yard, B., Waldherr, R., van der Woude, F. J. (2006). 15-Deoxyspergualin and cyclophosphamide, but not mycophenolate mofetil, prolong survival and attenuate renal disease in a murine model of ANCA-associated crescentic nephritis. Nephrol Dial Transplant 21: 58-63 [Abstract] [Full Text]
Schmitt, W. H., Birck, R., Heinzel, P. A., Gobel, U., Choi, M., Warnatz, K., Peter, H. H., van der Woude, F. J. (2005). Prolonged treatment of refractory Wegener's granulomatosis with 15-deoxyspergualin: an open study in seven patients. Nephrol Dial Transplant 20: 1083-1092 [Abstract] [Full Text]
Birck, R., Warnatz, K., Lorenz, H. M., Choi, M., Haubitz, M., Grunke, M., Peter, H. H., Kalden, J. R., Gobel, U., Drexler, J. M., Hotta, O., Nowack, R., van der Woude, F. J. (2003). 15-Deoxyspergualin in Patients with Refractory ANCA-Associated Systemic Vasculitis: A Six-Month Open-Label Trial to Evaluate Safety and Efficacy. J. Am. Soc. Nephrol. 14: 440-447 [Abstract] [Full Text]
Holcombe, H., Mellman, I., Janeway, C. A. Jr., Bottomly, K., Dittel, B. N. (2002). The Immunosuppressive Agent 15-Deoxyspergualin Functions by Inhibiting Cell Cycle Progression and Cytokine Production Following Naive T Cell Activation. J. Immunol. 169: 4982-4989 [Abstract] [Full Text]
Panjwani, N., Akbari, O., Garcia, S., Brazil, M., Stockinger, B. (1999). The HSC73 Molecular Chaperone: Involvement in MHC Class II Antigen Presentation. J. Immunol. 163: 1936-1942 [Abstract] [Full Text]